Cite
HARVARD Citation
Warren, R. et al. (2018). Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. Journal of the European Academy of Dermatology and Venereology. pp. 2178-2184. [Online].